Inhibitory action of glucosamine on platelet activation in guinea pigs

Inflammation Research

Volumn 54, Issue 12, 2005, Pages 493-499

  Lu Suguro, J F ^a,b   Hua, J ^a   Sakamoto, K ^b   Nagaoka, I ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b Koyo Chemical Co Ltd   (Japan)

Author keywords

ADP; Aggregation; Glucosamine; Guinea pig; Platelet

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTITHROMBOCYTIC AGENT; COLLAGEN; GLUCOSAMINE; THROMBOXANE A2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLEEDING TIME; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FEMALE; GUINEA PIG; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; PROSTAGLANDIN SYNTHESIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADMINISTRATION, ORAL; ANIMALS; BLEEDING TIME; BLOOD PLATELETS; BODY WEIGHT; CYTOPLASMIC GRANULES; FEMALE; GLUCOSAMINE; GUINEA PIGS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET COUNT; RECEPTORS, PURINERGIC P2; THROMBOXANE A2;

EID: 29944445825     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-005-1384-3     Document Type: Article

References (35)

1. Crolle G, D'Este E. Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opin 1980; 7: 104-9.
2. Drovani A, Bignamini AA, Rovati AL. Therapeutic activity of oral glucosamine sulfate in osteoarthritis: a placebo-control double-blind investigation. Clin Ther 1980; 3: 270-72.
3. Tapadinhas MJ, Rivera IC, Bignamini AA. Oral glucosamine sulphate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmatherapeutica 1982; 3: 157-68.
4. Vaz AL. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthritis of the knee in out-patients. Cuu Med Res Opin 1982; 8: 145-9.
5. Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999; 26: 2423-30.
6. Noack W, Fischer M, Forster KK, Rovati LC, Setnikar I. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2: 51-9.
7. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251-6.
8. Towheed TE, Anastassiades TP. Glucosamine therapy for osteoarthritis. J Rheumatol 1999; 26: 2294-7.
9. Meininger CJ, Kelly KA, Li H, Haynes TE, Wu G. Glucosamine inhibits inducible nitric oxide synthesis. Biochem Biophys Res Commun 2000; 279: 234-9.
10. Gouze JN, Bordji K, Gulberti S, Terlain B, Netter P, Magdalou J, et al. Interleukin-1beta down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1 beta-mediated effects in rat chondrocytes. Arthritis Rheum 2001; 44: 351-60.
11. Setnikar I, Pacini MA, Revel L. Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneimittelforschung 1991; 41: 542-5.
12. McCarty MF. Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier-implications for use of glucosamine in inflammatory disorders. Med Hypotheses 1998; 51: 11-5.
13. Hua J, Sakamoto K, Nagaoka I. Inhibitory actions of glucosamine, a therapeutic agent for osteoarthritis, on the functions of neutrophils. J Leukoc Biol 2002; 71: 632-40.
14. Kikuchi Y, Sato K, Ohki H, Kaneko T. Optically accessible micro-channels formed in a single-crystal silicon substrate for studies of blood rheology. Microvasc Res 1992; 44: 226-40.
15. Hua J, Suguro S, Iwabuchi K, Tsutsumi-Ishii Y, Sakamoto K, Nagaoka I. Glucosamine, a naturally occurring amino monosaccharide suppresses the ADP-mediated platelet activation in humans. Inflamm Res 2004; 53: 680-8.
16. Crouch SP, Kozlowski R, Slater KJ, Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods 1993; 160: 81-8.
17. Bauch HJ, Ilsemann K, Beeck H, Voss B, Balleisen L. A double antibody sandwich microELISA for measuring human platelet factor 4. Thromb Res 1985; 37: 573-82.
18. MacDonald JD, Remington BJ, Rodgers GM. The skin bleeding time test as a predictor of brain bleeding time in a rat model. Thromb Res 1994; 76: 535-40.
19. Liang Z, Leslie J, Adebowale A, Ashraf M, Eddington ND. Determination of the nutraceutical, glucosamine hydrochloride, in raw materials, dosage forms and plasma using pre-column derivatization with ultraviolet HPLC. J Pharm Biomed Anal 1999; 20: 807-14.
20. d 7.9 μmol/L) platelet binding sites for ADP and competition by ADP analogues. Blood 1988; 71: 110-6.
21. 3H]-2-methylthio ADP to rat platelets-effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994; 269: 772-7
22. Clutton P, Folts JD, Freedman JE. Pharmacological control of platelet function. Pharmacol Res 2001; 44: 255-64.
23. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222-32.
24. Berg JM, Tymoczko JL, Stryer L. Enzymes: Basic concepts and kinetics. Biochemistry. Vol 5. New York: W. H. Freeman and Company, 2002: 189-225.
25. McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469-75.
26. Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP, Orth MW. Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 2000; 8: 258-65.
27. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394-405.
28. Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, et al. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 1998; 422: 291-5.
29. Savi P, Laplace MC, Herbert JM. Evidence for the existence of two different ADP-binding sites on rat platelets. Thromb Res 1994; 76: 157-69.
30. George JN. Platelets. Lancet 2000; 355: 1531-9.
31. Martin J, Quinn MD, Desmond J, Fitzgerald MD. Ticlopidine and Clopidogrel. Circulation 1999; 100: 1667-72.
32. Kam PCA, Nethery CM. The thienopyridine derivatives (platelet adenosine diphosphate receptor antagonists), pharmacology and clinical developments. Anaesthesia 2003; 58: 28-35.
33. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353:227-31.
34. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ 2002; 325: 828-31.
35. Bjorkman DJ. The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins. Am J Med 1998; 105: 8S-12S.